BioMS Medical to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference

EDMONTON, Oct. 31 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS), aleading developer in the treatment of multiple sclerosis (MS), today announcedthat Mr. Kevin Giese, President and CEO, will present at the Acumen BioFinRodman and Renshaw 9th Annual Healthcare Conference in New York.

The Conference will include presentations by over 350 companies, as wellas experts from the medical, scientific and investment communities. TheConference will be attended by investors, venture capitalists, companyexecutives, scientists and other industry leaders.

BioMS Medical is a biotechnology company engaged in the development andcommercialization of novel therapeutic technologies. BioMS Medical's leadtechnology, MBP8298, is for the treatment of multiple sclerosis and is beingevaluated in two pivotal phase III clinical trials for secondary progressiveMS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the UnitedStates. It additionally is being evaluated for relapsing remitting MS patientsin a Phase II trial in Europe entitled MINDSET-01. For further informationplease visit our website at www.biomsmedical.com.

This news release may contain certain forward-looking statements thatreflect the current views and/or expectations of BioMS Medical with respect toits performance, business and future events. Such statements are subject to anumber of risks, uncertainties and assumptions. Actual results and events mayvary significantly.WHEN: Monday, November 5th at 3:20 pm (Local Time) WHERE: New York Palace Hotel, New York About Acumen BioFin Rodman and Renshaw 9th Annual Healthcare Conference -----------------------------------------------------------------------

SOURCE BioMS Medical Corp.

Latest Press Release on General News

Precision oncology company Flindr Therapeutics announces €20 million Series A financing to advance first-in-class small molecule inhibitors

V-Bio Ventures leads international syndicate which includes Johnson & Johnson Innovation – JJDC, Inc., QBIC Fund, Flanders Future Tech Fund, Curie Capital as well as seed investor...

Rett Syndrome Research Trust Partners with Vivalink to Shift Symptom Assessment Paradigms in Rett Syndrome

Vivalink's remote patient monitoring solutions accelerate research into rare neurological disorder CAMPBELL, Calif. , April 23, 2024 /PRNewswire/ -- Vivalink , a leading pro...

World IBS Day - April 19th: Raising Awareness for Everyone with IBS

Debunking myths about Irritable Bowel Syndrome TORONTO , April 18, 2024 /PRNewswire/ -- IBS is a chronic gastrointestinal disorder with symptoms like abdominal pain, bloating,...

Important step taken on the Canada Disability Benefit in Budget 2024, but funding falls short

More work must be done to lift Canadians with disabilities out of poverty TORONTO , April 17, 2024 /CNW/ - The federal government has taken an important step on the Canada Di...

Hydrinity Accelerated Skin Science Introduces MicroFusion Technology and Expands Facial Skincare Line with PRELUDE Facial Treatment Cleanser and HYDRI-C Vitamin C Moisturizer

The Next Generation Technology with the Power to Transform Skin MONROE, La. , April 15, 2024 /PRNewswire/ -- Hydrinity Accelerated Skin Science announced today the launch of t...